RECURRENT GLIOSARCOMA
Clinical trials for RECURRENT GLIOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GLIOSARCOMA trials appear
Sign up with your email to follow new studies for RECURRENT GLIOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Second radiation blast targets recurrent brain tumors
Disease control Recruiting nowThis early-phase trial tests a new way to give radiation to people whose glioblastoma (a severe brain cancer) has come back after initial treatment. About 28 adults will receive focused radiation over 1 to 3 weeks, with different schedules to find the safest dose. The goal is to …
Matched conditions: RECURRENT GLIOSARCOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Genetically modified immune cells take on deadly brain tumors
Disease control Recruiting nowThis early-stage trial tests genetically engineered natural killer (NK) cells in 25 people with recurrent glioblastoma, an aggressive brain cancer. The cells are designed to resist the tumor's defenses. The main goal is to find a safe dose and check for side effects, while also w…
Matched conditions: RECURRENT GLIOSARCOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope for aggressive brain cancer? early trial of ERAS-801 begins
Disease control Recruiting nowThis early-phase trial tests the safety of a drug called ERAS-801 in 10 adults with recurrent glioblastoma, a fast-growing brain cancer. The drug targets a protein called EGFR that is overactive in many of these tumors. Researchers will also check if the drug affects tumor activi…
Matched conditions: RECURRENT GLIOSARCOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Cold virus hijacked to attack returning brain tumors in early trial
Disease control Recruiting nowThis early-phase trial tests a modified cold virus (DNX-2401) that is loaded into donor stem cells and injected into the brain's blood supply to target recurrent high-grade gliomas. The virus is designed to infect and kill cancer cells while leaving healthy cells alone. The study…
Matched conditions: RECURRENT GLIOSARCOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental drug aims to boost immune attack on aggressive brain tumors
Disease control Recruiting nowThis phase 2 trial tests a new drug called GI-102, alone or with the immunotherapy pembrolizumab, given before surgery to people with recurrent or progressive glioblastoma (a fast-growing brain cancer). The goal is to see if these drugs can increase cancer-fighting immune cells i…
Matched conditions: RECURRENT GLIOSARCOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug combo aims to boost immune attack on returning brain tumors
Disease control Recruiting nowThis study tests two immunotherapy drugs, efineptakin alfa and pembrolizumab, in people whose glioblastoma (a type of brain cancer) has returned after standard treatment. The goal is to see if this combination can help the immune system fight the tumor and improve survival. About…
Matched conditions: RECURRENT GLIOSARCOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC